flutamide has been researched along with goserelin in 193 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (3.63) | 18.7374 |
| 1990's | 94 (48.70) | 18.2507 |
| 2000's | 64 (33.16) | 29.6817 |
| 2010's | 27 (13.99) | 24.3611 |
| 2020's | 1 (0.52) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jorion, JL | 1 |
| Haefliger, JM | 1 |
| Huben, RP | 1 |
| Schmeller, N | 1 |
| Armitage, TG; Cooper, EH; Denis, L; Newling, DW; Richards, BR; Robinson, MR; Smith, PH; Sylvester, R | 1 |
| Bono, A; Carneiro de Moura, JL; De Pauw, M; Denis, L; Keuppens, F; Mahler, C; Newling, D; Robinson, M; Smith, P; Sylvester, R | 1 |
| Baldelli, S; Cellerino, R; Menichetti, ET; Miseria, S; Murer, B; Torresi, U; Tummarello, D | 1 |
| Fischer, M; Flamm, J; Höltl, W; Pflüger, H; Tomschi, W | 1 |
| Altwein, JE; Boccardo, F; Haefliger, JM; Holdaway, IM; Jordaan, JP; Klippel, F; Lunglmayr, G; Tyrrell, CJ; Varenhorst, E | 1 |
| Horlbeck, R; Jurincic, CD; Klippel, KF | 1 |
| Berná, L; Blanco, R; Carrió, I; Estorch, M; Germá, JR; Torres, G | 1 |
| Denis, L | 3 |
| Ayub, M; Levell, MJ | 1 |
| Armitage, TG; Bono, A; Calais da Silva, F; Debruyne, F; Denis, L; Robinson, P; Smith, PH; Sylvester, R | 1 |
| De Pauw, M; Denis, L; Newling, DW; Robinson, MR; Sylvester, R | 1 |
| Christensen, I; Denis, L; Iversen, P; Suciu, S; Sylvester, R | 2 |
| Bond, A; Carvalho, AP; De Pauw, M; Denis, L; Keuppens, F; Newling, D; Ongena, P; Smith, P; Sylvester, R; Vermeylen, K | 1 |
| Christensen, MG; Friis, E; Hornbøl, P; Hvidt, V; Iversen, HG; Iversen, P; Klarskov, P; Krarup, T; Lund, F; Mogensen, P | 1 |
| Schulze, H; Senge, T | 1 |
| Bono, A; De Pauw, M; Denis, L; Keuppens, F; Mahler, C; Newling, D; Pinto de Carvalho, AP; Robinson, M; Smith, P; Sylvester, R | 1 |
| D'Eramo, G; Di Silverio, F; Sciarra, F | 1 |
| Hwang, YS; John, MJ; Krall, JM; McGowan, D; Perez, CA; Pilepich, MV | 1 |
| Bono, A; De Moura, JL; De Pauw, M; Denis, L; Keuppens, F; Mahler, C; Newling, D; Robinson, M; Smith, P; Sylvester, R | 1 |
| Guidez, C | 1 |
| Lunglmayr, G | 2 |
| Bono, A; De Moura, JL; De Pauw, M; Denis, L; Keuppens, F; Mahler, C; Newling, DW; Robinson, M; Smith, PH; Sylvester, R | 1 |
| Iversen, P | 1 |
| Cariou, G; Coloby, P; Colombel, P; Coulange, C; Fourcade, RO; Grise, P; Mangin, P; Poterre, M; Soret, JY | 1 |
| Boccardo, F; Cortellini, P; Decensi, A; Delli Ponti, U; Giuliani, L; Guarneri, D; Martorana, G; Oneto, F; Petracco, S; Rubagotti, A | 1 |
| Bono, A; Carvalho, AP; de Moura, JL; De Pauw, M; Denis, L; Newling, D; Ongena, P; Smith, P; Sylvester, R | 1 |
| Ceda, GP; Ceresini, G; Cortellini, P; Denti, L; Hoffman, AR; Valenti, G | 1 |
| Aaronson, N; Da Silva, FC | 1 |
| Kaldenhoff, H; Schulze, H; Senge, T | 1 |
| Bouffioux, C | 1 |
| Derde, MP; Kaufman, L; Mattelaer, J; Oosterlinck, W | 1 |
| Abellera, M; Chen, GT; Chiru, P; Hamilton, RJ; Ray, P; Spelbring, D; Vaida, F; Vijayakumar, S; Yang, FE | 1 |
| Cespedes, RD; Jackson, C; Peretsman, SJ; Thompson, IM | 1 |
| Crawford, ED | 1 |
| Mottrie, AM; Müller, SC; Stöckle, M; Voges, GE | 1 |
| Schulman, CC | 1 |
| Aprikian, AG; Armas, OA; Cohen, DW; Cordon-Cardo, C; Erlandson, R; Fair, WR; Melamed, J; Reuter, VE | 1 |
| Cheson, BD; Kaplan, RS; Phillips, PH | 1 |
| Block, N; Jones, J; Kolvenbag, G; Patterson, AL; Sarosdy, M; Schellhammer, P; Sharifi, R; Soloway, M; Venner, P; Vogelzang, N | 2 |
| Brogden, RN; Faulds, D | 1 |
| Huhtaniemi, I; Kangasniemi, M; Meistrich, ML; Wilson, G | 1 |
| Abrams, RA; al-Sarraf, M; Doggett, RL; John, MJ; Krall, JM; Lawton, CA; Pilepich, MV; Rotman, M; Rubin, P; Sause, WT | 1 |
| Debruyne, FM; Oosterhof, GO; Schulman, CC; van Cangh, PJ; Witjes, WP | 1 |
| Labrie, F | 1 |
| Begbie, SD; Bell, DR; Blome, SA; Stevens, MJ | 1 |
| Bottero, G; Buffa, G; Ferraris, V; Novella, V; Pacilli, N; Pisano, PF | 1 |
| Aprikian, AG; Cohen, D; Fair, WR; Reuter, V; Sogani, P | 1 |
| Dorr, RP; Lee, F; McHugh, TA; Siders, DB; Solomon, MH | 1 |
| Buffa, G; Ferraris, V; Pacilli, N; Pisano, PF | 1 |
| Denis, L; Newling, DW; Vermeylen, K | 1 |
| Christensen, IJ; Iversen, P; Klarskov, P; Rasmussen, F | 1 |
| Bono, A; Carneiro de Moura, JL; De Pauw, M; Denis, L; Keuppens, F; Mahler, C; Newling, D; Robinson, M; Sylvester, R; Whelan, P | 1 |
| Altwein, JE; Boccardo, F; Haefliger, JM; Holdaway, IM; Jordaan, JP; Klippel, F; Lunglmayr, G; Sotarauta, M; Tyrrell, CJ; Varenhorst, E | 1 |
| da Silva, FC | 1 |
| Heathcote, PS; Kateley, GD; Lloyd, S; Nicol, DL | 1 |
| Bono, A; Carnelro de Moura, JL; Denis, LJ; Depauw, M; Newling, D; Sylvester, R; Whelan, P | 1 |
| Waxman, J | 1 |
| Battaglia, M; Boccardo, F; Decensi, A; Giuliani, L; Guarneri, D; Martorana, G; Oneto, F; Pace, M; Rubagotti, A; Selvaggi, F | 1 |
| Fichtner, J; Hohenfellner, R; Mappes, C; Mottrie, AM; Stöckle, M; Störkel, S; Voges, GE | 1 |
| Aridogan, IA; Yachia, D | 1 |
| Andras, EJ; Brooks, CP; Chang, GC; Gilbert, RM; Leibenhaut, MH; Linstadt, DE; Rosenthal, SA; Stickney, DR; Wolkov, HB | 1 |
| Aaronson, NK; Casselman, J; da Silva, FC; Denis, L; Fava, C; Fossa, SD; Hetherington, J; Richards, B; Robinson, MR; Serbouti, S; Whelan, P | 1 |
| Ablondi, F; Cortellini, P; Denti, L; Ferretti, S; Pasolini, G; Sanfelici, L; Valenti, G | 1 |
| Scalliet, P | 1 |
| Jones, J; Kolvenbag, G; Patterson, AL; Sarosdy, M; Schellhammer, P; Sharifi, R; Soloway, MS; Venner, P; Vogelzang, N | 1 |
| Acar, O; Goldschmidt, AJ; Tunn, UW | 1 |
| Ago, CT; Asbell, SO; Brereton, HD; Leon, SA; Rotman, M; Tester, WJ | 1 |
| Block, NL; Chen, Y; Kolvenbag, GJ; Patterson, AL; Sarosdy, MF; Schellhammer, PF; Sharifi, R; Soloway, MS; Venner, PM; Vogelzang, NJ | 1 |
| Abrams, RA; Caplan, R; Cox, JD; Forman, JD; Fu, KK; Grignon, DJ; Hammond, EH; Lawton, CA; Mesic, J; Pajak, TF; Pilepich, MV; Sarkar, FH; Shipley, WU | 1 |
| Begg, CB; Cookson, MS; Dalbagni, G; Fair, WR; Herr, H; Reuter, VE; Russo, P; Sheinfeld, J; Sogani, PC | 1 |
| Aprikian, AG; Begg, CB; Cohen, D; Cookson, MS; Dalgabni, G; Fair, WR; Herr, H; Heston, WD; Reuter, VE; Russo, P; Sheinfeld, J; Sogani, P; Soloway, SM; Stroumbakis, N; Wang, Y | 1 |
| Debruyne, FM; Schulman, CC; Witjes, WP | 1 |
| Akaza, H; Aso, Y; Isaka, S; Kanetake, H; Koiso, K; Kotake, T; Usami, M | 1 |
| Block, NL; Kolvenbag, GJ; Patterson, AL; Sarosdy, MF; Schellenger, JJ; Schellhammer, PF; Sharifi, R; Soloway, MS; Venner, PM; Vogelzang, NJ | 1 |
| Anderson, PR; Hanks, GE; Hanlon, AL; Movsas, B | 1 |
| de Voogt, H; Denis, L; Sylvester, RJ | 1 |
| Bono, A; de Moura, JL; Denis, LJ; Keuppens, F; Newling, D; Smith, PH; Sylvester, R; Whelan, P | 1 |
| Block, NL; Chodak, GW; Klein, EA; Kolvenbag, GJ; Patterson, AL; Sarosdy, MF; Schellenger, JJ; Schellhammer, PF; Sharifi, R; Soloway, MS; Venner, PM; Vogelzang, NJ | 1 |
| Chatelain, C; Fourcade, RO | 1 |
| Hirao, Y; Ozono, S | 1 |
| Bryant, C; Campbell, J; Diamond, T; Lynch, W | 1 |
| Cole, BF; Curran, D; Denis, LJ; Hall, RR; Kiebert, GM; Rosendahl, I; Weeks, JC | 1 |
| Collinson, MP; Daniel, F; Teasdale, C; Tyrrell, CJ | 1 |
| Altinbaş, M; Cetin, M; Demirci, D; Güven, M; Unal, A; Unlühizarci, K | 1 |
| Altwein, J; Boyle, P; Denis, LJ; Griffiths, K; Kirby, R; Robertson, C; Schröder, F; Turkes, A | 1 |
| Block, NL; Kelley, RP; Kolvenbag, GJ; McLeod, DG; Patterson, AL; Sarosdy, MF; Schellhammer, PF; Sharifi, R; Soloway, MS; Venner, PM; Vogelzang, NJ | 1 |
| Higashi, T; Maruyama, Y; Nagayoshi, J | 1 |
| Barichello, M; Battaglia, M; Boccardo, F; Carmignani, G; Comeri, G; Conti, G; Cruciani, G; Dammino, S; Delliponti, U; Ditonno, P; Ferraris, V; Lilliu, S; Montefiore, F; Portoghese, F; Rubagotti, A; Spano, G | 1 |
| Carroll, K; Johnson, R; Kolvenbag, GJ; Sarosdy, MF; Schellhammer, PF | 1 |
| Altwein, JE; Boccardo, F; Haefliger, JM; Holdaway, IM; Jordaan, JP; Jurincic-Winkler, C; Klippel, F; Lunglmayr, G; Tyrrell, CJ; Varenhorst, E | 1 |
| Halachmi, S; Madeb, R; Madjar, S; Nativ, O; River, Y; Wald, M | 1 |
| Denham, J; Franklin, I; Joseph, D; Kovacev, O; Lamb, D; Mameghan, H; Matthews, J; North, J; Poulsen, M; Spry, N; Steigler, A; Turner, S | 1 |
| Baba, S; Egawa, S; Kuwao, S; Matsumoto, K; Mizoguchi, H; Takashima, R | 1 |
| Aizawa, Y; Ikemoto, I; Ohishi, Y; Wada, T; Yamazaki, H | 1 |
| Betancourt, JE; Fair, WR | 1 |
| Debruyne, FM; Witjes, WP | 1 |
| Debruyne, FM; Forster, G; Schulman, CC; Selvaggi, FP; Witjes, WP; Zlotta, AR | 1 |
| Fukunaga, M; Jo, Y; Sone, T; Tamada, T; Tanaka, H; Tomomitsu, T | 1 |
| Aoyagi, T; Hata, M; Hayakawa, K; Matsumoto, M; Miyaji, K | 1 |
| Bechev, R; Chakarov, S; Fachikov, Ts; Lazarov, Z; Rangelov, S | 1 |
| Bryc, W; Kokot, F; Nowicki, M | 1 |
| Hashimoto, H; Inada, F; Ishida, H; Kawakami, N; Kitahara, K; Masui, N; Saga, Y; Tokumitsu, M; Yachiku, S | 1 |
| Leibowitz, RL; Tucker, SJ | 1 |
| Mazeron, JJ; Noël, G | 1 |
| Collette, L; Denis, LJ; Schröder, FH; Studer, UE; Sylvester, RJ | 1 |
| Grignon, D; John, MJ; Lawton, C; Machtay, M; Mesic, JB; Pilepich, MV; Rubin, P; Sause, W; Winter, K | 1 |
| Fukuoka, H; Harada, M; Hosaka, M; Kitami, K; Miura, T; Moriyama, M; Noguchi, K; Uemura, H | 1 |
| Bryant, C; De Souza, P; Diamond, TH; Kersley, JH; Lynch, WJ; Smith, A; Winters, J | 1 |
| Plöen, L; Ritzen, EM; Setchell, BP | 1 |
| Candas, B; Cusan, L; Gomez, JL; Labrie, F | 1 |
| Fukuda, M; Fuse, H; Hirano, S; Takashima, H | 1 |
| Carroll, PR; Crawford, ED; DeVERE WHITE, R; Haas, G; Lowe, BA; Miller, GJ; Osswald, MB; Powell, IJ; Tangen, CM; Thompson, IM | 1 |
| Barichello, M; Battaglia, M; Boccardo, F; Carmignani, G; Comeri, G; Cortellini, P; Ferraris, V; Lilliu, S; Montefiore, F; Portoghese, F; Rigatti, P; Rubagotti, A; Usai, E | 1 |
| Akay, AF; Bircan, MK; Deniz, M; Göçmen, M; Nergiz, Y; Sahin, H | 1 |
| Heydon, K; Lawton, CA; Lu, JD; Machtay, M; Pilepich, MV; Roach, M; Rubin, P; Sause, WT; Shipley, WU; Wolkov, HB | 1 |
| Asbell, SO; Grignon, D; Lu, J; Mohiuddin, M; Pilepich, MV; Roach, M | 1 |
| Mizokami, A; Namiki, M | 1 |
| Duncan, WE; Harding, P; Howard, RS; McLeod, DG; Preston, DM; Torréns, JI | 1 |
| Agarwal, S; Bulpitt, CJ; Dockery, F; Rajkumar, C | 1 |
| Abrams, RA; Fu, KK; Grignon, DJ; Hammond, EH; Heydon, KH; Lawton, CA; Mesic, JB; Pollack, A; Porter, AT; Shipley, WU | 1 |
| Igaki, H; Kaizu, T; Karasawa, K; Matsuda, T; Niibe, Y; Shinohara, M; Tanaka, Y | 1 |
| Abdalla, I; Basu, A; Connell, PP; Jani, AB; Krauz, L; Vijayakumar, S | 1 |
| Atkinson, C; Christie, D; Denham, JW; Duchesne, G; Francis, L; Franklin, I; Joseph, D; Kovacev, O; Lamb, DS; Mameghan, H; Matthews, J; North, J; Poulsen, M; Robertson, R; Spry, NA; Tai, KH; Turner, S; Wynne, C | 1 |
| Budde, A; Caprano, J; Helpap, B; Hopfenmüller, W; Köllermann, J; Weidenfeld, H; Weidenfeld, M | 1 |
| Gerald, WL; Holzbeierlein, J; Lal, P; LaTulippe, E; Reuter, V; Ryan, C; Satagopan, J; Scardino, P; Scher, H; Smith, A; Smith, S; Zhang, L | 1 |
| Choudhury, AM; Tanvetyanon, T | 1 |
| Andrianne, R; Boca, P; Bonnet, P; Bouffioux, C; Coppens, L; de Leval, J; Jeukenne, M; Nicolas, H; Seidel, L; Wlatregny, D; Yousef, E | 1 |
| Aslan, P; Bryant, C; Bucci, J; Diamond, TH; Kersley, JH; Lynch, WB | 1 |
| D'Amico, AV; DellaCroce, A; Kantoff, PW; Loffredo, M; Manola, J; Renshaw, AA | 1 |
| Bowen, J; Crook, J; Eapen, L; Lim, J; Lockwood, G; Ludgate, C; Malone, S; Perry, G; Robertson, S | 1 |
| Miyakita, H | 1 |
| Gratzle, J; Jani, AB; Myers, M | 1 |
| Gratzle, J; Jani, AB | 1 |
| Atkinson, C; Christie, D; D'Este, C; Denham, JW; Duchesne, G; Franklin, I; Joseph, D; Kovacev, O; Lamb, DS; Mameghan, H; Matthews, J; North, J; Poulsen, M; Spry, NA; Steigler, A; Tai, KH; Turner, S; Wynne, C | 1 |
| Brereton, H; Feigenberg, S; Hanks, G; Konski, A; Watkins-Bruner, D | 1 |
| Desilvio, M; Lawton, CA; Pilepich, MV; Roach, M; Rubin, P; Sause, WT; Shipley, WU; Wolkov, HB | 1 |
| Fujisawa, M; Hara, I; Inoue, TA; Miyake, H; Sakai, I | 1 |
| Gerald, W; Lal, P; Reuter, V; Ryan, CJ; Satagopan, J; Scardino, P; Scher, HI; Smith, A | 1 |
| Arichi, N; Ichikawa, Y; Kishikawa, H; Nishimura, K; Tokugawa, S; Yoshioka, I | 1 |
| De Silvio, M; Fisher, B; Grignon, D; Hanks, G; Pollack, A; Rebbick, T; Roach, M; Rotman, M; Sandler, H; Shipley, WU; Watkins-Bruner, D; Wolkov, H | 1 |
| Hashimoto, Y; Ikarashi, T; Nishiyama, T; Takahashi, K; Wako, K | 1 |
| Bae, K; Hanks, G; Lawton, CA; Pilepich, M; Shipley, W | 1 |
| Bae, K; Grignon, D; Lawton, C; Lee, RJ; Pilepich, MV; Roach, M; Rubin, P; Speight, J; Valicenti, R; Wolkov, HB | 1 |
| Bae, K; Efstathiou, JA; Hanks, GE; Pilepich, MV; Sandler, HM; Shipley, WU; Smith, MR | 1 |
| Whelan, P | 1 |
| Chen, MH; D'Amico, AV; Kantoff, PW; Loffredo, B; Renshaw, AA | 1 |
| Bowen, J; Crook, J; Eapen, L; Lockwood, G; Ludgate, C; Malone, S; Perry, G; Robertson, S | 1 |
| Kempkensteffen, C; Kleinschmidt, K; Köllermann, J; Pantel, K; Rau, T; Schostak, M; Weikert, S | 1 |
| Gao, X; Lu, X; Sun, YH; Tang, YJ; Zhou, T | 1 |
| Crook, JM; Eapen, L; Fung, S; Lockwood, G; Ludgate, C; Malone, S; Owen, J; Perry, G; Robertson, S | 1 |
| Bae, K; Hanks, GE; Hussain, MH; Ray, ME; Sandler, HM; Shipley, WU | 1 |
| Burri, RJ; Cesaretti, JA; Ho, AY; Stock, RG; Stone, NN | 1 |
| Alexander, A; Bowen, J; Crook, J; Jones, S; Ludgate, C; Malone, S; Pai, H; Truong, P | 1 |
| Cronin, AM; Eastham, JA; Lowrance, WT; Maschino, AC; Rabbani, F; Yee, DS | 1 |
| Hara, N; Hoshii, T; Isahaya, E; Nishiyama, T; Takahashi, K; Takizawa, I | 3 |
| Antczak, A; Baczyk, M; Kwias, Z; Martenka, P; Milecki, P; Skowronek, J | 1 |
| Bjartell, A; Dahlman, A; Edsjö, A; Fine, SW; Gerald, W; Halldén, C; Lilja, H; Persson, JL | 1 |
| Atkinson, C; Christie, D; D'Este, C; Denham, JW; Joseph, D; Lamb, DS; Matthews, J; North, J; Spry, NA; Steigler, A; Tai, KH; Turner, S; Wynne, C | 1 |
| Hara, N; Hoshii, T; Isahaya, E; Ishizaki, F; Nishiyama, T; Takahashi, K; Takizawa, I | 1 |
| Kobayashi, M; Kurokawa, S; Morita, T; Nukui, A; Suzuki, K | 1 |
| Amin, MB; Bruner, DW; Chetner, MP; Hunt, D; Husain, SM; Jones, CU; Leibenhaut, MH; McGowan, DG; Rotman, M; Sandler, HM; Shipley, WU; Souhami, L | 1 |
| Bhinder, A; Clinton, SK; Friedman, A; Jain, HV | 1 |
| Berglund, RK; Canby-Hagino, ED; Carroll, PR; Crawford, ED; deVere White, R; Haas, GP; Hemstreet, GP; Klein, EA; Lowe, BA; Powell, IJ; Tangen, CM; Thompson, IM | 1 |
| Both, S; Guzzo, TJ; Haas, NB; Hwang, WT; Jang, JW; Vapiwala, N; Wein, AJ | 1 |
| Antes, G; Dahm, P; Grobe, HR; Kunath, F; Meerpohl, JJ; Motschall, E; Rücker, G; Wullich, B | 1 |
| Amin, MB; Balogh, AG; Bauman, GS; Chinn, DM; Dignam, JJ; Duclos, M; Gomella, LG; Gore, EM; Hunt, D; Lukka, HR; Pisansky, TM; Rosenthal, SA; Rotman, MZ; Sandler, HM; Seider, MJ; Shipley, WU | 1 |
| Bristow, RG; Dal Pra, A; Locke, JA; Supiot, S; Warde, P | 1 |
| Bahary, JP; Chafe, S; Efstathiou, JA; Gore, E; Husain, SM; Jones, CU; Leibenhaut, MH; McGowan, DG; Paulus, R; Raben, A; Rotman, M; Sandler, HM; Shipley, WU; Smith, MR; Souhami, L; Voog, JC; Zeitzer, KL | 1 |
| Ding, K; He, W; Liu, S; Wu, H; Zhang, T | 1 |
| Bedi, M; Brereton, HD; Dignam, JJ; Grignon, DJ; Hanks, GE; Horwitz, EM; Kim, H; Kwok, Y; Lawton, CAF; Lepor, H; Lin, X; Parliament, MB; Pisansky, TM; Rabinovitch, R; Roach, M; Rosenthal, SA; Sandler, HM; Venkatesan, VM; Zeitzer, KL | 1 |
| Cassidy-Bushrow, AE; Haque, R; Keating, NL; Potosky, AL; Tsai, HT; UlcickasYood, M; Van Den Eeden, SK; Xu, X | 1 |
| García-Perdomo, HA; Reis, LO; Zani, EL | 1 |
| Abdullaev, NA; Bakarev, MA; Kachesov, IV; Levin, VP; Neimark, AI | 1 |
| Dicker, AP; Gore, EM; Hartford, AC; Horwitz, EM; Hsu, IC; Jones, CU; Kim, HE; Kwok, Y; Lawton, CAF; Lee, WR; Michalski, JM; Moughan, J; Pisansky, TM; Pryzant, RM; Rabinovitch, R; Roach, M; Rotman, M; Sandler, HM; Seider, MJ; Shipley, WU; Thomas, CR; Yamoah, K; Zeitzer, KL | 1 |
| Bryant, AK; Deka, R; McKay, R; Murphy, JD; Nalawade, V; Rose, BS; Sarkar, RR; Simpson, DR | 1 |
| Chen, C; Li, J; Shen, P; Wu, B; Wu, F; Xu, T; Yin, X; Yu, L | 1 |
16 review(s) available for flutamide and goserelin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Goserelin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in prostate cancer.
Topics: Absorption; Aged; Antineoplastic Combined Chemotherapy Protocols; Estramustine; Estrogens; Flutamide; Gonadotropins; Goserelin; Humans; Male; Orchiectomy; Prostatic Neoplasms; Steroids | 1995 |
Use of neoadjuvant androgen deprivation therapy in clinically localized prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Flutamide; Goserelin; Humans; Male; Preoperative Care; Prostatectomy; Prostatic Neoplasms | 1993 |
Role of maximal androgen blockade in advanced prostate cancer.
Topics: Combined Modality Therapy; Drug Therapy, Combination; Flutamide; Goserelin; Humans; Male; Orchiectomy; Prognosis; Prostatic Neoplasms; Survival Analysis; Treatment Outcome | 1994 |
Androgen deprivation for prostatic carcinoma: a rationale for choosing components.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Flutamide; Goserelin; Humans; Imidazoles; Imidazolidines; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1998 |
[Total androgen blockade--concept, theory, method and clinical application].
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Chlormadinone Acetate; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Neoplasms, Hormone-Dependent; Orchiectomy; Prostatic Neoplasms | 1998 |
[Successful complete androgen blockade (CAB) therapy for prostatic cancer detected from multiple lung metastases: a case report].
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Drug Therapy, Combination; Flutamide; Goserelin; Humans; Lung Neoplasms; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Radiography; Treatment Outcome | 2001 |
[Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials].
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Male; Multicenter Studies as Topic; Prostatic Neoplasms; Survival Analysis; Treatment Outcome | 2001 |
[Prostatic cancer with multiple pulmonary metastases treated successfully with hormonal therapy: a case report].
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Diethylstilbestrol; Drug Administration Schedule; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Lung Neoplasms; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Tomography, X-Ray Computed | 2002 |
[Total androgen blockade].
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Castration; Chlormadinone Acetate; Drug Therapy, Combination; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Nitriles; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Tosyl Compounds | 2002 |
Rotational 3D-conformal radiation therapy (conformation therapy) combined with hormone therapy for the treatment of stage B2/C prostate cancer in Japanese men.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Chlormadinone Acetate; Diethylstilbestrol; Disease-Free Survival; Flutamide; Follow-Up Studies; Gastrointestinal Diseases; Goserelin; Humans; Imaging, Three-Dimensional; Japan; Life Tables; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prostatic Neoplasms; Radiation Injuries; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Retrospective Studies; Rotation; Survival Analysis; Treatment Outcome; Urination Disorders | 2003 |
[Hormonal therapy for prostatic cancer--state of the art].
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Castration; Chemotherapy, Adjuvant; Diethylstilbestrol; Drug Therapy, Combination; Estrogens; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Male; Meta-Analysis as Topic; Prostatectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic | 2005 |
First-line treatment of metastatic prostate cancer. Androgen suppression for symptomatic disease.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Neoplasms; Cyproterone; Estrogens; Flutamide; Goserelin; Humans; Male; Neoplasms, Hormone-Dependent; Orchiectomy; Practice Guidelines as Topic; Prostatic Neoplasms; Time Factors; Treatment Outcome | 2013 |
Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Disease Progression; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Medication Adherence; Nitriles; Orchiectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Tosyl Compounds; Triptorelin Pamoate | 2014 |
Synergistic action of image-guided radiotherapy and androgen deprivation therapy.
Topics: Androgen Antagonists; Androstenes; Benzamides; Biomarkers; Combined Modality Therapy; Dose-Response Relationship, Radiation; Flutamide; Goserelin; Humans; Male; Neoplasm Recurrence, Local; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Radiotherapy, Image-Guided; Risk Assessment; Treatment Outcome | 2015 |
Estrogen therapy in patients with prostate cancer: a contemporary systematic review.
Topics: Anilides; Antineoplastic Agents, Hormonal; Diethylstilbestrol; Estrogens, Non-Steroidal; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Nitriles; Orchiectomy; Prostatic Neoplasms; Tosyl Compounds | 2018 |
102 trial(s) available for flutamide and goserelin
| Article | Year |
|---|---|
[Randomized study comparing zoladex versus zoladex plus flutamide in treatment of advanced cancer of the prostate].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Delayed-Action Preparations; Flutamide; Goserelin; Humans; Male; Neoplasm Recurrence, Local; Prostate; Prostatic Neoplasms | 1992 |
Hormone therapy of prostatic bone metastases.
Topics: Actuarial Analysis; Androgen Antagonists; Bone Neoplasms; Combined Modality Therapy; Diethylstilbestrol; Estrogens; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Ketoconazole; Leuprolide; Male; Neoplasms, Hormone-Dependent; Orchiectomy; Prostatic Neoplasms; Remission Induction; Spironolactone; Survival Rate | 1992 |
[The role of LH-RH analogues in the treatment of prostate cancer. Report of a conference organized by ICI-Pharma laboratories (part 2)].
Topics: Adenocarcinoma; Drug Therapy, Combination; Flutamide; Goserelin; Humans; Male; Neoplasm Staging; Orchiectomy; Patient Satisfaction; Prostatic Neoplasms; Survival Rate | 1991 |
Total androgen ablation: European experience. The EORTC GU Group.
Topics: Aged; Buserelin; Flutamide; Goserelin; Humans; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms | 1991 |
Complete androgen deprivation prior to radical prostatectomy in patients with stage T3 cancer of the prostate.
Topics: Aged; Buserelin; Combined Modality Therapy; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Male; Pilot Projects; Preoperative Care; Prostatectomy; Prostatic Neoplasms; Time Factors | 1991 |
A multicenter randomized trial comparing the luteinizing hormone-releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer. The International Prostate Cancer Study Group.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Delayed-Action Preparations; Drug Tolerance; Flutamide; Goserelin; Humans; Male; Prostatic Neoplasms; Remission Induction; Time Factors; United Kingdom | 1991 |
Combined treatment (goserelin plus flutamide) versus monotherapy (goserelin alone) in advanced prostate cancer: a randomized study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Carcinoma; Flutamide; Follow-Up Studies; Goserelin; Humans; Male; Middle Aged; Prostatic Neoplasms; Remission Induction; Survival Rate | 1991 |
Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer. A subanalysis of EORTC trial 30853. The EORTC Urological Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Buserelin; Flutamide; Follow-Up Studies; Goserelin; Humans; Male; Orchiectomy; Prostatic Neoplasms; Radionuclide Imaging; Randomized Controlled Trials as Topic; Survival Rate | 1990 |
Comparability of EORTC and DAPROCA studies in advanced prostatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Flutamide; Goserelin; Humans; Male; Orchiectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate | 1990 |
Zoladex and flutamide versus bilateral orchiectomy. A randomized phase III EORTC 30853 study. The EORTC GU Group.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Buserelin; Flutamide; Goserelin; Humans; Male; Middle Aged; Multicenter Studies as Topic; Orchiectomy; Prognosis; Prostatic Neoplasms; Radionuclide Imaging; Randomized Controlled Trials as Topic; Survival Rate | 1990 |
A phase III trial of zoladex and flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Flutamide; Follow-Up Studies; Goserelin; Humans; Male; Middle Aged; Orchiectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate | 1990 |
Zoladex and flutamide versus orchiectomy in the treatment of advanced prostatic cancer. A combined analysis of two European studies, EORTC 30853 and DAPROCA 86.
Topics: Antineoplastic Combined Chemotherapy Protocols; Buserelin; Flutamide; Goserelin; Humans; Male; Orchiectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate | 1990 |
Complete androgen blockade: data from an EORTC 30853 trial.
Topics: Aged; Anilides; Buserelin; Combined Modality Therapy; Europe; Flutamide; Goserelin; Humans; Male; Middle Aged; Multicenter Studies as Topic; Orchiectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate | 1990 |
Advanced prostatic cancer: clinical and hormonal response to flutamide in patients pretreated with LHRH analogue and cyproterone acetate.
Topics: Aged; Androgen Antagonists; Anilides; Buserelin; Clinical Trials as Topic; Cyproterone; Cyproterone Acetate; Drug Therapy, Combination; Flutamide; Goserelin; Humans; Male; Middle Aged; Prostatic Neoplasms; Random Allocation | 1990 |
Phase II Radiation Therapy Oncology Group study of hormonal cytoreduction with flutamide and Zoladex in locally advanced carcinoma of the prostate treated with definitive radiotherapy.
Topics: Buserelin; Diarrhea; Flutamide; Goserelin; Humans; Male; Prostatic Neoplasms; Radiotherapy | 1990 |
Orchidectomy versus Zoladex plus Eulexin in patients with metastatic prostate cancer (EORTC 30853).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Drug Combinations; Drug Evaluation; Europe; Flutamide; Goserelin; Humans; Male; Orchiectomy; Prostatic Neoplasms; Risk Factors | 1990 |
[How can a nursing team participate in a clinical trial? Zoladex, flutamide trial].
Topics: Buserelin; Clinical Trials as Topic; Flutamide; Goserelin; Humans; Job Description; Male; Nursing Staff, Hospital; Prostatic Neoplasms | 1990 |
A multicenter trial comparing the luteinizing hormone releasing hormone analog Zoladex, with Zoladex plus flutamide in the treatment of advanced prostate cancer. The International Prostate Cancer Study Group.
Topics: Buserelin; Flutamide; Goserelin; Humans; Male; Prostatic Neoplasms | 1990 |
Orchidectomy vs. Zoladex plus flutamide in patients with metastatic prostate cancer. The EORTC GU Group.
Topics: Aged; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Buserelin; Carcinoma; Combined Modality Therapy; Flutamide; Follow-Up Studies; Goserelin; Humans; Liver Function Tests; Male; Orchiectomy; Prospective Studies; Prostatic Neoplasms; Survival Rate | 1990 |
Zoladex plus flutamide vs. orchidectomy for advanced prostatic cancer. Danish Prostatic Cancer Group (DAPROCA).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Combined Modality Therapy; Flutamide; Follow-Up Studies; Goserelin; Humans; Male; Middle Aged; Orchiectomy; Prostatic Neoplasms; Survival Rate | 1990 |
Total androgen blockade with Zoladex plus flutamide vs. Zoladex alone in advanced prostatic carcinoma: interim report of a multicenter, double-blind, placebo-controlled study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Double-Blind Method; Flutamide; Follow-Up Studies; Goserelin; Humans; Male; Middle Aged; Prostatic Neoplasms; Survival Rate | 1990 |
Zoladex with or without flutamide in the treatment of locally advanced or metastatic prostate cancer: interim analysis of an ongoing PONCAP study. Italian Prostatic Cancer Project (PONCAP).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Buserelin; Flutamide; Follow-Up Studies; Goserelin; Humans; Male; Neoplasm Staging; Prostatic Neoplasms; Survival Rate | 1990 |
Zoladex and flutamide vs orchidectomy: a phase III EORTC 30853 trial. EORTC Urological Group.
Topics: Anilides; Buserelin; Clinical Trials as Topic; Europe; Flutamide; Goserelin; Humans; Male; Multicenter Studies as Topic; Orchiectomy; Prognosis; Prospective Studies; Prostatic Neoplasms; Random Allocation | 1989 |
'Zoladex' versus 'Zoladex' plus flutamide in the treatment of advanced prostate cancer. First interim analysis of an international trial. International Prostate Cancer Study Group.
Topics: Aged; Anilides; Buserelin; Clinical Trials as Topic; Drug Therapy, Combination; Flutamide; Goserelin; Humans; International Cooperation; Male; Multicenter Studies as Topic; Prognosis; Prostatic Neoplasms; Random Allocation | 1989 |
Quality of life assessment in prostatic cancer.
Topics: Buserelin; Clinical Trials as Topic; Europe; Flutamide; Goserelin; Humans; Male; Orchiectomy; Prostatic Neoplasms; Quality of Life; Surveys and Questionnaires | 1988 |
Evaluation of total versus partial androgen blockade in the treatment of advanced prostatic cancer.
Topics: Androgen Antagonists; Androgens; Buserelin; Flutamide; Goserelin; Humans; Male; Multicenter Studies as Topic; Orchiectomy; Prospective Studies; Prostatic Neoplasms; Random Allocation | 1988 |
Total androgen blockade in advanced prostatic cancer. Critical review and personal experience.
Topics: Androgen Antagonists; Buserelin; Cyproterone; Cyproterone Acetate; Flutamide; Goserelin; Humans; Male; Multicenter Studies as Topic; Orchiectomy; Prostatic Neoplasms; Time Factors | 1988 |
Prognostic factors in advanced prostatic carcinoma treated with total androgen blockade. Flutamide with orchiectomy or with LHRH analogues. A Belgian multicentric study of 546 patients.
Topics: Aged; Analysis of Variance; Androgen Antagonists; Antineoplastic Agents, Hormonal; Castration; Combined Modality Therapy; Disease-Free Survival; Flutamide; Goserelin; Humans; Male; Middle Aged; Multivariate Analysis; Prognosis; Prostatic Neoplasms; Triptorelin Pamoate | 1995 |
Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma.
Topics: Adenocarcinoma; Cell Division; Combined Modality Therapy; Diploidy; Flutamide; Goserelin; Humans; Male; Neoplasm Staging; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms | 1994 |
A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Confidence Intervals; Double-Blind Method; Flutamide; Follow-Up Studies; Goserelin; Humans; Leuprolide; Male; Middle Aged; Nitriles; Proportional Hazards Models; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Regression Analysis; Survival Rate; Tosyl Compounds; Treatment Failure | 1995 |
Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Combined Modality Therapy; Flutamide; Goserelin; Humans; Male; Middle Aged; Neoplasm Staging; Prostatic Neoplasms | 1995 |
A phase III trial (RTOG 8610) comparing external-beam irradiation plus short-term maximal androgen blockade with radiation therapy alone for locally advanced prostate cancer. The Radiation Therapy Oncology Group.
Topics: Chemotherapy, Adjuvant; Flutamide; Goserelin; Humans; Male; Prostatic Neoplasms; Radiotherapy, High-Energy | 1994 |
A multicentre trial of combined neoadjuvant androgen blockade with Zoladex and flutamide prior to radical prostatectomy in prostate cancer. The European Study Group on Neoadjuvant Treatment.
Topics: Chemotherapy, Adjuvant; Flutamide; Goserelin; Humans; Male; Neoplasm Staging; Prostatectomy; Prostatic Neoplasms | 1994 |
Prolonged hypogonadism after pulsed gonadotropin-releasing hormone agonist for prostate cancer.
Topics: Combined Modality Therapy; Erectile Dysfunction; Flutamide; Follicle Stimulating Hormone; Goserelin; Humans; Luteinizing Hormone; Male; Prostatic Neoplasms; Testis; Testosterone | 1994 |
[Treatment of prostatic carcinoma in clinical stage C. Comparison between radiotherapy plus hormonal therapy after progression and immediate hormonal therapy].
Topics: Aged; Aged, 80 and over; Combined Modality Therapy; Flutamide; Follow-Up Studies; Goserelin; Humans; Infant; Male; Middle Aged; Neoplasm Staging; Prostatic Neoplasms | 1994 |
Use of neoadjuvant androgen deprivation therapy in clinically localized prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Flutamide; Goserelin; Humans; Male; Preoperative Care; Prostatectomy; Prostatic Neoplasms | 1993 |
Hormone ablation therapy as neoadjuvant treatment to radical prostatectomy.
Topics: Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Flutamide; Goserelin; Humans; Leuprolide; Male; Middle Aged; Preoperative Care; Prostatectomy; Prostatic Neoplasms | 1993 |
Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Analysis of the criteria of evaluation used in the European Organization for Research and Treatment of Cancer--Genitourinary Group Study 30853.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Flutamide; Goserelin; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Orchiectomy; Prospective Studies; Prostatic Neoplasms | 1993 |
Long-term results of Danish Prostatic Cancer Group trial 86. Goserelin acetate plus flutamide versus orchiectomy in advanced prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Flutamide; Follow-Up Studies; Goserelin; Humans; Male; Orchiectomy; Prostatic Neoplasms; Survival Rate | 1993 |
Orchidectomy versus goserelin plus flutamide in patients with metastatic prostate cancer (EORTC 30853). European Organization for Research and Treatment of Cancer--Genitourinary Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Flutamide; Goserelin; Humans; Male; Middle Aged; Orchiectomy; Prostatic Neoplasms; Survival Rate | 1993 |
Multicenter randomized trial comparing Zoladex with Zoladex plus flutamide in the treatment of advanced prostate cancer. Survival update. International Prostate Cancer Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Flutamide; Goserelin; Humans; Male; Prostatic Neoplasms; Survival Rate | 1993 |
Quality of life in prostatic carcinoma.
Topics: Activities of Daily Living; Flutamide; Goserelin; Humans; Interpersonal Relations; Male; Orchiectomy; Pain; Prostatic Neoplasms; Quality of Life; Sexual Behavior; Surveys and Questionnaires; Urination Disorders | 1993 |
Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center.
Topics: Aged; Bone Neoplasms; Combined Modality Therapy; Drug Therapy, Combination; Flutamide; Follow-Up Studies; Goserelin; Humans; Male; Middle Aged; Orchiectomy; Prognosis; Prostatic Neoplasms; Survival Analysis | 1993 |
Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. The Italian Prostatic Cancer Project (PONCAP) Study Group.
Topics: Acid Phosphatase; Aged; Aged, 80 and over; Flutamide; Goserelin; Humans; Male; Middle Aged; Prostatic Neoplasms; Time Factors | 1993 |
Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Flutamide; Follow-Up Studies; Goserelin; Humans; Leuprolide; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1996 |
The quality of life of patients with newly diagnosed M1 prostate cancer: experience with EORTC clinical trial 30853.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Flutamide; Follow-Up Studies; Goserelin; Humans; Male; Medical Staff, Hospital; Middle Aged; Orchiectomy; Patient Compliance; Prostatic Neoplasms; Quality of Life; Surveys and Questionnaires | 1996 |
A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Drug Synergism; Flutamide; Follow-Up Studies; Goserelin; Humans; Male; Nitriles; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Survival Analysis; Tosyl Compounds | 1996 |
Effects of androgen deprivation prior to radical prostatectomy in 375 patients.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Cyproterone Acetate; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Middle Aged; Neoplasm Staging; Prostate; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Time Factors | 1996 |
Development of anemia and recovery in prostate cancer patients treated with combined androgen blockade and radiotherapy.
Topics: Aged; Androgen Antagonists; Anemia; Antineoplastic Agents, Hormonal; Black People; Combined Modality Therapy; Drug Therapy, Combination; Flutamide; Goserelin; Hemoglobins; Humans; Male; Pelvis; Prostatic Neoplasms; Remission Induction; White People | 1996 |
A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group.
Topics: Adenocarcinoma; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Double-Blind Method; Flutamide; Goserelin; Humans; Leuprolide; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1996 |
Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: results of a phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease-Free Survival; Flutamide; Goserelin; Humans; Lymph Node Excision; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Treatment Outcome | 1997 |
The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Drug Therapy, Combination; Flutamide; Goserelin; Humans; Male; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Preoperative Care; Prostatic Neoplasms | 1997 |
Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma. The European Study Group on Neoadjuvant Treatmen
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Flutamide; Goserelin; Humans; Male; Neoplasm Staging; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Time Factors | 1997 |
Recommended dose of flutamide with LH-RH agonist therapy in patients with advanced prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemical and Drug Induced Liver Injury; Diarrhea; Dose-Response Relationship, Drug; Flutamide; Follow-Up Studies; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Middle Aged; Prospective Studies; Prostatic Neoplasms | 1996 |
Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Flutamide; Follow-Up Studies; Goserelin; Humans; Leuprolide; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Survival Rate; Tosyl Compounds | 1997 |
The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials. European Organization for Research and Treatment of Cancer (EORTC) Genito-Urinary Tract Cancer Cooperative Group.
Topics: Aged; Analysis of Variance; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Buserelin; Combined Modality Therapy; Cyproterone Acetate; Disease-Free Survival; Flutamide; Goserelin; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Orchiectomy; Prognosis; Proportional Hazards Models; Prostatic Neoplasms; Risk Assessment; Survival Rate | 1998 |
Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma; Disease Progression; Disease-Free Survival; Flutamide; Goserelin; Humans; Male; Middle Aged; Orchiectomy; Prognosis; Prospective Studies; Prostatic Neoplasms; Survival Rate; Treatment Outcome | 1998 |
Comparison of goserelin and leuprolide in combined androgen blockade therapy.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Double-Blind Method; Flutamide; Goserelin; Humans; Leuprolide; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Survival Rate; Tosyl Compounds | 1998 |
Quality-adjusted survival (Q-TWiST) analysis of EORTC trial 30853: comparing goserelin acetate and flutamide with bilateral orchiectomy in patients with metastatic prostate cancer. European Organization for Research and Treatment of Cancer.
Topics: Antineoplastic Agents, Hormonal; Combined Modality Therapy; Flutamide; Goserelin; Humans; Male; Neoplasm Metastasis; Orchiectomy; Pain Measurement; Prostatic Neoplasms; Quality of Life; Quality-Adjusted Life Years; Survival Analysis | 1999 |
Finasteride in association with either flutamide or goserelin as combination hormonal therapy in patients with stage M1 carcinoma of the prostate gland. International Prostate Health Council (IPHC) Trial Study Group.
Topics: 5-alpha Reductase Inhibitors; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Dihydrotestosterone; Enzyme Inhibitors; Finasteride; Flutamide; Follicle Stimulating Hormone; Goserelin; Humans; Luteinizing Hormone; Male; Middle Aged; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms | 1999 |
Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues. The Casodex Combination Study Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Black People; Bone Neoplasms; Cohort Studies; Disease Progression; Disease-Free Survival; Double-Blind Method; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Tosyl Compounds; White People | 1999 |
Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Consumer Product Safety; Disease Progression; Disease-Free Survival; Erectile Dysfunction; Flutamide; Goserelin; Humans; Italy; Male; Middle Aged; Nitriles; Proportional Hazards Models; Prostatic Neoplasms; Quality of Life; Survival Rate; Tosyl Compounds | 1999 |
Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy?
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Drug Administration Schedule; Drug Therapy, Combination; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Survival Rate; Tosyl Compounds | 2000 |
Comparison of an LH-RH analogue (Goeserelin acetate, 'Zoladex') with combined androgen blockade in advanced prostate cancer: final survival results of an international multicentre randomized-trial. International Prostate Cancer Study Group.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Flutamide; Follow-Up Studies; Goserelin; Humans; Male; Middle Aged; Neoplasm Staging; Prostatic Neoplasms; Survival Rate | 2000 |
A quality assurance audit: phase III trial of maximal androgen deprivation in prostate cancer (TROG 96.01).
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Costs and Cost Analysis; Flutamide; Goserelin; Humans; Male; Medical Audit; Prostatic Neoplasms; Quality Assurance, Health Care; Radiotherapy, Adjuvant; Time Factors | 2000 |
Neoadjuvant hormonal therapy prior to radical prostatectomy: the European experience.
Topics: Androgens; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Europe; Flutamide; Goserelin; Humans; Male; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms | 2000 |
4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer.
Topics: Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Disease-Free Survival; Europe; Flutamide; Follow-Up Studies; Goserelin; Humans; Male; Neoplasm Staging; Prospective Studies; Prostate; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Time Factors | 2000 |
Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Finasteride; Flutamide; Follow-Up Studies; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Middle Aged; Neoplasm Staging; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Flutamide; Follow-Up Studies; Gonadotropin-Releasing Hormone; Goserelin; Humans; Life Tables; Male; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prostatic Neoplasms; Radiotherapy, High-Energy; Survival Analysis; Treatment Outcome | 2001 |
Inhibition of PSA flare in prostate cancer patients by administration of flutamide for 2 weeks before initiation of treatment with slow-releasing LH-RH agonist.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Delayed-Action Preparations; Drug Administration Schedule; Flutamide; Goserelin; Humans; Injections, Subcutaneous; Leuprolide; Male; Middle Aged; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms | 2001 |
The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bone Density; Cross-Over Studies; Diphosphonates; Double-Blind Method; Drug Therapy, Combination; Flutamide; Goserelin; Humans; Injections, Intravenous; Male; Osteoporosis; Pamidronate; Prostate-Specific Antigen; Prostatic Neoplasms; Testosterone | 2001 |
Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer?
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Therapy, Combination; Flutamide; Follow-Up Studies; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Longitudinal Studies; Male; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome; Triptorelin Pamoate | 2002 |
Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial.
Topics: Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Flutamide; Goserelin; Humans; Male; Middle Aged; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Tosyl Compounds; Treatment Outcome | 2002 |
Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86-10.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Disease-Free Survival; Flutamide; Goserelin; Humans; Male; Middle Aged; Prostatic Neoplasms; Recurrence; Salvage Therapy; Time Factors; Treatment Outcome | 2002 |
Testosterone suppression in men with prostate cancer is associated with increased arterial stiffness.
Topics: Age Factors; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Arteries; Cardiovascular Diseases; Flutamide; Goserelin; Hemodynamics; Humans; Leuprolide; Male; Middle Aged; Prostatic Neoplasms; Vascular Patency | 2002 |
Prostate cancer DNA ploidy and response to salvage hormone therapy after radiotherapy with or without short-term total androgen blockade: an analysis of RTOG 8610.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Combined Modality Therapy; Diploidy; DNA, Neoplasm; Flutamide; Goserelin; Humans; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Proportional Hazards Models; Prostatic Neoplasms; Retrospective Studies; Salvage Therapy; Survival Rate | 2003 |
Acceptability of short term neo-adjuvant androgen deprivation in patients with locally advanced prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Erectile Dysfunction; Flutamide; Goserelin; Humans; Intestines; Male; Middle Aged; Neoadjuvant Therapy; Prostatic Neoplasms; Surveys and Questionnaires; Treatment Outcome; Urinary Bladder | 2003 |
Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial.
Topics: Adenocarcinoma; Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Disease Progression; Drug Administration Schedule; Flutamide; Goserelin; Humans; Injections, Subcutaneous; Male; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms | 2002 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Goserelin; Humans; Leuprolide; Male; Middle Aged; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy, Conformal; Survival Analysis | 2004 |
Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Goserelin; Humans; Male; Middle Aged; Neoadjuvant Therapy; Prostate-Specific Antigen; Prostatic Neoplasms; Statistics, Nonparametric; Survival Rate | 2004 |
Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Disease-Free Survival; Flutamide; Goserelin; Humans; Male; Middle Aged; Neoadjuvant Therapy; Prostatic Neoplasms | 2005 |
Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: A secondary analysis of RTOG protocol 86-10.
Topics: Analysis of Variance; Androgen Antagonists; Antineoplastic Agents, Hormonal; Disease-Free Survival; Flutamide; Goserelin; Humans; Male; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Salvage Therapy; Treatment Failure | 2006 |
Racial differences in CYP3A4 genotype and survival among men treated on Radiation Therapy Oncology Group (RTOG) 9202: a phase III randomized trial.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Black People; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Disease Progression; Flutamide; Genotype; Goserelin; Humans; Male; Neoplasm Proteins; Practice Guidelines as Topic; Prostate-Specific Antigen; Prostatic Neoplasms; Regression Analysis; Survival; White People | 2007 |
Long-term treatment sequelae after external beam irradiation with or without hormonal manipulation for adenocarcinoma of the prostate: analysis of radiation therapy oncology group studies 85-31, 86-10, and 92-02.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Combined Modality Therapy; Flutamide; Follow-Up Studies; Gastrointestinal Tract; Goserelin; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Radiation Injuries; Urogenital System | 2008 |
Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Combined Modality Therapy; Disease-Free Survival; Flutamide; Follow-Up Studies; Goserelin; Humans; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Prostatic Neoplasms; Survival Rate | 2008 |
Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Cardiovascular Diseases; Flutamide; Goserelin; Humans; Male; Middle Aged; Multivariate Analysis; Prostatic Neoplasms; Time Factors | 2008 |
Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Middle Aged; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Factors | 2008 |
Final report of multicenter Canadian Phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Canada; Disease-Free Survival; Drug Administration Schedule; Flutamide; Goserelin; Humans; Male; Middle Aged; Neoadjuvant Therapy; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate | 2009 |
Twenty-four-month postradiation prostate biopsies are strongly predictive of 7-year disease-free survival: results from a Canadian randomized trial.
Topics: Aged; Aged, 80 and over; Biopsy; Canada; Disease-Free Survival; Flutamide; Goserelin; Humans; Male; Middle Aged; Predictive Value of Tests; Prognosis; Prostatic Neoplasms; Radiotherapy Dosage; Treatment Outcome | 2009 |
Potential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trial.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Disease-Free Survival; Dose Fractionation, Radiation; Endpoint Determination; Flutamide; Follow-Up Studies; Goserelin; Humans; Karnofsky Performance Status; Male; Middle Aged; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy, Adjuvant; Research Design; Treatment Failure; Treatment Outcome | 2009 |
Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinically localized prostate cancer? An analysis of the 3- versus 8-month randomized trial.
Topics: Adenocarcinoma; Aged; Analysis of Variance; Androgen Antagonists; Antineoplastic Agents, Hormonal; Disease-Free Survival; Flutamide; Goserelin; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms; Time Factors | 2010 |
Long-term follow-up of 3-month neoadjuvant hormone therapy before radical prostatectomy in a randomized trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Epidemiologic Methods; Flutamide; Goserelin; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prostatectomy; Prostatic Neoplasms; Treatment Outcome | 2010 |
Bone metabolic disorder in patients with prostate cancer receiving androgen deprivation therapy (ADT): impact of ADT on the growth hormone/insulin-like growth factor-1/parathyroid hormone axis.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Density; Bone Diseases, Metabolic; Flutamide; Goserelin; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Orchiectomy; Parathyroid Hormone; Prospective Studies; Prostatic Neoplasms | 2010 |
Benefit of whole pelvic radiotherapy combined with neoadjuvant androgen deprivation for the high-risk prostate cancer.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Goserelin; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Poland; Prospective Studies; Prostatic Neoplasms; Radiotherapy, Conformal; Risk Factors | 2009 |
Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Australia; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Flutamide; Follow-Up Studies; Goserelin; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; New Zealand; Prostatectomy; Prostatic Neoplasms; Radiotherapy, Adjuvant; Time Factors; Treatment Outcome | 2011 |
Radiotherapy and short-term androgen deprivation for localized prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Erectile Dysfunction; Flutamide; Follow-Up Studies; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Middle Aged; Multivariate Analysis; Prostate; Prostatic Neoplasms; Radiotherapy; Radiotherapy Dosage; Risk; Survival Rate | 2011 |
Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest Oncology Group Study 9109.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Disease Progression; Drug Therapy, Combination; Flutamide; Follow-Up Studies; Goserelin; Humans; Infusions, Subcutaneous; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Prospective Studies; Prostatic Neoplasms; Treatment Outcome | 2012 |
Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Disease-Free Survival; Flutamide; Follow-Up Studies; Goserelin; Humans; Leuprolide; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy; Time Factors; Tosyl Compounds; Treatment Outcome | 2015 |
Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08.
Topics: Aged; Antineoplastic Agents, Hormonal; Cardiovascular Diseases; Flutamide; Follow-Up Studies; Goserelin; Humans; Incidence; Leuprolide; Male; Middle Aged; Proportional Hazards Models; Prostatic Neoplasms; Retrospective Studies; Survival Rate; Time Factors | 2016 |
Clinical evaluation of tamsulosin in the relief of lower urinary tract symptoms in advanced prostate cancer patients.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Antineoplastic Combined Chemotherapy Protocols; Flutamide; Goserelin; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prostatic Neoplasms; Quality of Life; Severity of Illness Index; Sulfonamides; Tamsulosin; Time Factors; Urodynamics | 2017 |
Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Combined Modality Therapy; Disease-Free Survival; Flutamide; Follow-Up Studies; Goserelin; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Time Factors; Treatment Outcome | 2017 |
Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Canada; Chemoradiotherapy; Dose Fractionation, Radiation; Drug Administration Schedule; Flutamide; Goserelin; Humans; Kallikreins; Leuprolide; Male; Neoplasm Grading; Neoplasm Staging; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms; Time Factors; United States | 2018 |
76 other study(ies) available for flutamide and goserelin
| Article | Year |
|---|---|
Idiopathic resistance to luteinizing hormone-releasing hormone analogue in a patient with prostatic carcinoma.
Topics: Adenocarcinoma; Aged; Drug Resistance; Flutamide; Follicle Stimulating Hormone; Goserelin; Humans; Luteinizing Hormone; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Testosterone | 1992 |
[A 79-year-old man with metastatic prostate cancer, treated with Zoladex, flutamide, calcitonin and Ostac, suffers from frequent troublesome sweating with palpitation and angina pectoris, especially at night. Is there a therapy?].
Topics: Aged; Androgen Antagonists; Angina Pectoris; Buserelin; Calcitonin; Cyproterone; Cyproterone Acetate; Flutamide; Goserelin; Humans; Hyperhidrosis; Male; Prostatic Neoplasms | 1992 |
Prostatic specific antigen and the prediction of prognosis in metastatic prostatic cancer.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Buserelin; Flutamide; Goserelin; Humans; Male; Orchiectomy; Predictive Value of Tests; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Radionuclide Imaging; Survival Rate | 1990 |
Lymphangitic carcinomas of the lung as presentation of prostatic cancer. A case report.
Topics: Buserelin; Carcinoma; Flutamide; Goserelin; Humans; Lung Neoplasms; Lymphangitis; Male; Middle Aged; Prostatic Neoplasms | 1991 |
Bone marrow regeneration after hormonal therapy in patients with bone metastases from prostate carcinoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Bone Marrow; Bone Neoplasms; Buserelin; Flutamide; Goserelin; Humans; Male; Middle Aged; Organotechnetium Compounds; Prostatic Neoplasms; Radionuclide Imaging; Regeneration | 1991 |
Maximal androgen blockade in prostatic cancer.
Topics: Androgen Antagonists; Buserelin; Flutamide; Goserelin; Humans; Imidazoles; Imidazolidines; Leuprolide; Male; Orchiectomy; Prostatic Neoplasms | 1991 |
Suppression of plasma androgens by the antiandrogen flutamide in prostatic cancer patients treated with Zoladex, a GnRH analogue.
Topics: 17-alpha-Hydroxyprogesterone; Aged; Aged, 80 and over; Androgens; Androstenedione; Anilides; Antineoplastic Agents; Buserelin; Dehydroepiandrosterone; Depression, Chemical; Flutamide; Goserelin; Humans; Hydroxyprogesterones; Male; Orchiectomy; Prostatic Neoplasms; Testosterone | 1990 |
EORTC protocol 30853: orchidectomy versus zoladex plus flutamide in the management of metastatic carcinoma of the prostate. Interim statistical analysis of the side effects of treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Buserelin; Flutamide; Goserelin; Humans; Male; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms | 1990 |
Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate.
Topics: Acid Phosphatase; Aged; Androgen Antagonists; Buserelin; Cyproterone; Cyproterone Acetate; Drug Therapy, Combination; Flutamide; Goserelin; Humans; Luteinizing Hormone; Male; Premedication; Prostatic Neoplasms; Testosterone; Time Factors | 1990 |
Androgens do not regulate the growth hormone response to GHRH in elderly men.
Topics: Aged; Aging; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Flutamide; Goserelin; Growth Hormone; Growth Hormone-Releasing Hormone; Humans; Male; Middle Aged; Prostatic Neoplasms; Testosterone | 1989 |
LHRH analogues in combination with an anti-androgen in the treatment of advanced disease.
Topics: Androgen Antagonists; Buserelin; Drug Therapy, Combination; Flutamide; Goserelin; Humans; Male; Prostatic Neoplasms | 1989 |
The potential for normal tissue dose reduction with neoadjuvant hormonal therapy in conformal treatment planning for stage C prostate cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Flutamide; Goserelin; Humans; Male; Prostate; Prostatic Neoplasms; Radiotherapy Dosage; Rectum; Retrospective Studies; Urinary Bladder | 1995 |
Protection of the germinal epithelium in the rat from the cytotoxic effects of chemotherapy by a luteinizing hormone-releasing hormone agonist and antiandrogen therapy.
Topics: Animals; Drug Therapy, Combination; Epithelium; Flutamide; Goserelin; Male; Procarbazine; Rats; Rats, Sprague-Dawley; Seminiferous Tubules | 1995 |
A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Controlled Clinical Trials as Topic; Flutamide; Goserelin; Humans; Leuprolide; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1995 |
Hormone therapy prior to radical prostatectomy in patients with clinical stage C prostate cancer.
Topics: Chemotherapy, Adjuvant; Drug Therapy, Combination; Flutamide; Goserelin; Humans; Male; Neoplasm Staging; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Treatment Outcome | 1994 |
Neoadjuvant androgen blockade prior to prostatectomy: a retrospective study and critical review.
Topics: Aged; Chemotherapy, Adjuvant; Drug Therapy, Combination; Flutamide; Goserelin; Humans; Male; Middle Aged; Neoplasm Staging; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Retrospective Studies | 1994 |
Clinical trials referral resource. Prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Lymphatic Metastasis; Male; Middle Aged; Palliative Care; Prostatectomy; Prostatic Neoplasms; Quality of Life | 1994 |
Protection against procarbazine-induced testicular damage by GnRH-agonist and antiandrogen treatment in the rat.
Topics: Androgen Antagonists; Animals; Drug Combinations; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Hormones; Male; Procarbazine; Rats; Spermatogenesis; Testis | 1995 |
[New approaches in the treatment of prostatic cancer].
Topics: Chemotherapy, Adjuvant; Flutamide; Goserelin; Humans; Male; Prostatic Neoplasms | 1994 |
Prostate cancer.
Topics: Adult; Combined Modality Therapy; Flutamide; Goserelin; Humans; Male; Orchiectomy; Prostatic Neoplasms; Survival Rate | 1994 |
[Clinical significance of the local response to prostatic carcinoma during hormonotherapy].
Topics: Actuarial Analysis; Combined Modality Therapy; Drug Therapy, Combination; Flutamide; Follow-Up Studies; Goserelin; Humans; Male; Organ Size; Prognosis; Prostate; Prostatectomy; Prostatic Neoplasms; Retrospective Studies; Survival Analysis; Testosterone; Treatment Outcome | 1993 |
Advanced prostate cancer. The role of high priced hormone therapy.
Topics: Combined Modality Therapy; Cyproterone Acetate; Diagnosis-Related Groups; Drug Costs; Drug Therapy, Combination; Flutamide; Goserelin; Health Care Costs; Humans; Male; Orchiectomy; Prostatic Neoplasms; Queensland | 1993 |
What is the correct hormonal treatment for prostate cancer?
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Male; Prostatic Neoplasms | 1993 |
Maximum androgen deprivation prior to radical retropubic prostatectomy in patients with stage T3 adenocarcinoma of the prostate.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Flutamide; Goserelin; Humans; Male; Middle Aged; Neoplasm Staging; Prostatectomy; Prostatic Neoplasms | 1995 |
The use of a removable stent in patients with prostate cancer and obstruction.
Topics: Aged; Antineoplastic Agents, Hormonal; Catheters, Indwelling; Equipment Design; Flutamide; Follow-Up Studies; Goserelin; Humans; Male; Orchiectomy; Prostatic Neoplasms; Stents; Time Factors; Urethra; Urinary Bladder Neck Obstruction; Urinary Catheterization; Urinary Retention | 1996 |
Flutamide-associated liver toxicity during treatment with total androgen suppression and radiation therapy for prostate cancer.
Topics: Aged; Alanine Transaminase; Alkaline Phosphatase; Androgen Antagonists; Antineoplastic Agents, Hormonal; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; Clinical Enzyme Tests; Cohort Studies; Combined Modality Therapy; Flutamide; Gastrointestinal Diseases; Goserelin; Humans; Liver Function Tests; Male; Prospective Studies; Prostatic Neoplasms; Radiotherapy Dosage | 1996 |
Effects of androgen suppression by gonadotropin-releasing hormone agonist and flutamide on lipid metabolism in men with prostate cancer: focus on lipoprotein(a).
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Apolipoprotein A-I; Body Mass Index; Cholesterol; Cholesterol, HDL; Estradiol; Flutamide; Goserelin; Humans; Lipids; Lipoprotein(a); Male; Middle Aged; Prostatic Neoplasms; Testosterone; Triglycerides | 1996 |
Carcinoma of the prostate: neoadjuvant hormonotherapy followed by radiotherapy.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Diethylstilbestrol; Flutamide; Goserelin; Humans; Male; Prostatic Neoplasms | 1996 |
p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Flutamide; Gene Expression Regulation, Neoplastic; Genes, p53; Goserelin; Humans; Male; Middle Aged; Mutation; Prognosis; Prostatic Neoplasms; Radiotherapy, Adjuvant; Survival Analysis; Tumor Suppressor Protein p53 | 1997 |
Prostate cancer patient subsets showing improved bNED control with adjuvant androgen deprivation.
Topics: Analysis of Variance; Androgen Antagonists; Antineoplastic Agents, Hormonal; Case-Control Studies; Combined Modality Therapy; Flutamide; Goserelin; Humans; Leuprolide; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies | 1997 |
The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Amino Acids; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone and Bones; Bone Density; Calcium; Carcinoma; Drug Administration Schedule; Etidronic Acid; Evaluation Studies as Topic; Femur Neck; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Longitudinal Studies; Lumbar Vertebrae; Male; Middle Aged; Osteocalcin; Parathyroid Hormone; Prostate-Specific Antigen; Prostatic Neoplasms; Remission Induction; Testosterone; Tomography, X-Ray Computed; Vitamin D | 1998 |
Response of carcinoma of the prostate to withdrawal of flutamide.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Disease Progression; Flutamide; Goserelin; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms | 1993 |
Frequency of flutamide induced hepatotoxicity in patients with prostate carcinoma.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Contraindications; Flutamide; Goserelin; Humans; Liver; Liver Failure, Acute; Liver Function Tests; Male; Middle Aged; Orchiectomy; Prospective Studies; Prostatic Neoplasms | 1999 |
[Serum concentrations of flutamide and goserelin in a prostate cancer patient with obstructive nephropathy: a case report].
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Goserelin; Humans; Hydronephrosis; Male; Prostatic Neoplasms; Ureteral Obstruction | 1999 |
Numb chin syndrome as the presenting symptom of metastatic prostate carcinoma.
Topics: Aged; Antineoplastic Agents, Hormonal; Biopsy; Carcinoma; Chin; Drug Therapy, Combination; Flutamide; Goserelin; Humans; Hypesthesia; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Syndrome | 2000 |
A pilot study of intermittent androgen ablation in advanced prostate cancer in Japanese men.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Alkaline Phosphatase; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Disease Progression; Drug Administration Schedule; Flutamide; Follow-Up Studies; Fractures, Bone; Goserelin; Humans; Leuprolide; Lumbar Vertebrae; Male; Middle Aged; Pilot Projects; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Remission Induction; Survival Rate; Testosterone; Treatment Outcome | 2000 |
[Changes in liver function induced by flutamide in patients with prostate cancer (studies in patients treated with total androgen blockage)].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Chemical and Drug Induced Liver Injury; Cholinesterases; Drug Therapy, Combination; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Liver Diseases; Liver Function Tests; Male; Middle Aged; Prostatic Neoplasms | 2000 |
Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Hormonal; Biopsy; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Flutamide; Follow-Up Studies; Goserelin; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Time Factors | 2000 |
Biochemical markers for the detection of bone metastasis in patients with prostate cancer: diagnostic efficacy and the effect of hormonal therapy.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Bone Resorption; Flutamide; Goserelin; Humans; Male; Osteogenesis; Prostatic Neoplasms; Radionuclide Imaging; ROC Curve | 2001 |
Prostate cancer with multiple lung metastases in a hemodialysis patient.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Drug Therapy, Combination; Flutamide; Goserelin; Humans; Lung Neoplasms; Male; Prostatic Neoplasms; Radiography, Thoracic; Renal Dialysis; Tomography, X-Ray Computed | 2000 |
[Radical prostatectomy with broadened scope of indications - analysis of early experience].
Topics: Acid Phosphatase; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Biopsy; Flutamide; Goserelin; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms | 1999 |
Hormonal regulation of appetite and body mass in patients with advanced prostate cancer treated with combined androgen blockade.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Appetite; Body Constitution; Body Mass Index; Body Weight; Estradiol; Flutamide; Goserelin; Humans; Insulin; Leptin; Male; Middle Aged; Neuropeptide Y; Prostatic Neoplasms; Regression Analysis; Testosterone | 2001 |
Why phase III trials of maximal androgen blockade versus castration in M1 prostate cancer rarely show statistically significant differences.
Topics: Androgen Antagonists; Anilides; Clinical Trials, Phase III as Topic; Cyproterone Acetate; Factor Analysis, Statistical; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Imidazoles; Imidazolidines; Leuprolide; Male; Meta-Analysis as Topic; Nitriles; Orchiectomy; Prognosis; Prostatic Neoplasms; Research Design; Survival Analysis; Tosyl Compounds; Treatment Outcome | 2001 |
Effect of local heating of rat testes after suppression of spermatogenesis by pretreatment with a GnRH agonist and an anti-androgen.
Topics: Analysis of Variance; Androgen Antagonists; Animals; Epididymis; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Hot Temperature; Male; Organ Size; Random Allocation; Rats; Rats, Sprague-Dawley; Sperm Count; Spermatogenesis; Statistics, Nonparametric; Testis | 2002 |
Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5-year followup, Phase II Southwest Oncology Group Study 9109.
Topics: Aged; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Feasibility Studies; Flutamide; Goserelin; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prostatectomy; Prostatic Neoplasms; Survival Rate | 2002 |
The effects of GnRH analogues and antiandrogenes in preventing the gonadotoxic effects of COPP chemotherapy.
Topics: Androgen Antagonists; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Flutamide; Goserelin; Male; Prednisone; Procarbazine; Random Allocation; Rats; Rats, Sprague-Dawley; Vincristine | 2001 |
Race and survival of men treated for prostate cancer on radiation therapy oncology group phase III randomized trials.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Black or African American; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Flutamide; Goserelin; Humans; Male; Multivariate Analysis; Prognosis; Proportional Hazards Models; Prospective Studies; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; White People | 2003 |
Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
Topics: Absorptiometry, Photon; Adenocarcinoma; Aged; Amino Acids; Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents, Hormonal; Biomarkers; Bone Density; Bone Remodeling; Calcium; Drug Therapy, Combination; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Neoplasms, Hormone-Dependent; Nitriles; Orchiectomy; Osteoporosis; Prospective Studies; Prostatic Neoplasms; Testosterone; Tosyl Compounds | 2002 |
Impact of hormone therapy when combined with external beam radiotherapy for early-stage, intermediate-, or high-risk prostate cancer.
Topics: Adenocarcinoma; Aged; Anilides; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Flutamide; Goserelin; Humans; Male; Neoadjuvant Therapy; Nitriles; Prostatic Neoplasms; Survival Analysis; Tosyl Compounds | 2003 |
Prognosis of stage pT0 after prolonged neoadjuvant endocrine therapy of prostate cancer: a matched-pair analysis.
Topics: Anilides; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Flutamide; Follow-Up Studies; Goserelin; Humans; Leuprolide; Male; Matched-Pair Analysis; Neoplasm Staging; Nitriles; Prognosis; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Time Factors; Tosyl Compounds | 2004 |
Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance.
Topics: Algorithms; Antineoplastic Agents, Hormonal; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Therapy, Combination; Flutamide; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Goserelin; Humans; In Situ Hybridization, Fluorescence; Male; Prostatic Neoplasms | 2004 |
Fatal acute tumor lysis syndrome, hepatic encephalopathy and flare phenomenon following combined androgen blockade.
Topics: Aged; Androgen Antagonists; Drug Therapy, Combination; Fatal Outcome; Flutamide; Goserelin; Hepatic Encephalopathy; Humans; Male; Prostatic Neoplasms; Tumor Lysis Syndrome | 2004 |
Osteoporosis and spinal fractures in men with prostate cancer: risk factors and effects of androgen deprivation therapy.
Topics: Aged; Alcohol Drinking; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Comorbidity; Flutamide; Goserelin; Humans; Male; Multivariate Analysis; Nitriles; Osteoporosis; Prostatic Neoplasms; Retrospective Studies; Risk Factors; Spinal Fractures; Time Factors; Tosyl Compounds; Vitamin D | 2004 |
Impact of hormone therapy on acute radiotherapy toxicity in the treatment of prostate cancer.
Topics: Aged; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Brachytherapy; Cohort Studies; Flutamide; Gastrointestinal Tract; Goserelin; Hormones; Humans; Leuprolide; Male; Middle Aged; Nitriles; Prognosis; Prostatic Neoplasms; Radiation Injuries; Radiotherapy; Radiotherapy Dosage; Regression Analysis; Testosterone; Time Factors; Tosyl Compounds; Treatment Outcome; Urogenital System | 2005 |
Late radiotherapy toxicity after prostate cancer treatment: influence of hormonal therapy.
Topics: Aged; Anilides; Antineoplastic Agents, Hormonal; Flutamide; Gastrointestinal Diseases; Goserelin; Humans; Leuprolide; Male; Male Urogenital Diseases; Nitriles; Prostatic Neoplasms; Radiation Injuries; Time Factors; Tosyl Compounds | 2005 |
Long-term hormone therapy and radiation is cost-effective for patients with locally advanced prostate carcinoma.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Cost-Benefit Analysis; Flutamide; Goserelin; Humans; Male; Markov Chains; Monte Carlo Method; Neoadjuvant Therapy; Prostatic Neoplasms; Quality-Adjusted Life Years; Radiotherapy, Conformal; Randomized Controlled Trials as Topic | 2006 |
The limited significance of a longer duration of neoadjuvant hormonal therapy prior to radical prostatectomy for high-risk prostate cancer in Japanese men.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Japan; Leuprolide; Male; Middle Aged; Neoadjuvant Therapy; Nitriles; Preoperative Care; Prostatectomy; Prostatic Neoplasms; Retrospective Studies; Risk Factors; Time Factors; Tosyl Compounds | 2006 |
Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: an early predictor of relapse or incomplete androgen suppression.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Flutamide; Gene Expression; Gene Expression Profiling; Goserelin; Humans; Male; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Predictive Value of Tests; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Treatment Failure | 2006 |
Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Biopsy, Needle; Drug Resistance, Neoplasm; Drug Therapy, Combination; Endosonography; Flutamide; Follow-Up Studies; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Magnetic Resonance Imaging; Male; Neoplasm Staging; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Tomography, X-Ray Computed; Tosyl Compounds; Treatment Outcome | 2007 |
The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Biomarkers, Tumor; Dihydrotestosterone; Disease Progression; Flutamide; Goserelin; Humans; Leuprolide; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Orchiectomy; Prognosis; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Testosterone | 2007 |
Editorial comment on: Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.
Topics: Antineoplastic Agents, Hormonal; Cardiovascular Diseases; Flutamide; Goserelin; Humans; Male; Prostatic Neoplasms | 2008 |
Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment.
Topics: Aged; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Flutamide; Follow-Up Studies; Goserelin; Humans; Leuprolide; Male; Multivariate Analysis; Neoadjuvant Therapy; Neoplastic Cells, Circulating; Nitriles; Prognosis; Prostatectomy; Prostatic Neoplasms; Tosyl Compounds | 2008 |
Neoadjuvant hormonal deprivation for patients undergoing radical prostatectomy.
Topics: Aged; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Dose-Response Relationship, Drug; Flutamide; Goserelin; Humans; Male; Middle Aged; Neoadjuvant Therapy; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Retrospective Studies; Treatment Outcome | 2009 |
Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.
Topics: Analysis of Variance; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Biopsy; Brachytherapy; Flutamide; Follow-Up Studies; Goserelin; Humans; Iodine Radioisotopes; Leuprolide; Male; Nitriles; Palladium; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Radiotherapy Dosage; Relative Biological Effectiveness; Tosyl Compounds; Treatment Failure | 2009 |
Effect of androgen deprivation therapy on the expression of prostate cancer biomarkers MSMB and MSMB-binding protein CRISP3.
Topics: Aged; Androgen Antagonists; Biomarkers, Tumor; Carcinoma; Epigenesis, Genetic; Flutamide; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genotype; Goserelin; Humans; Male; Microarray Analysis; Middle Aged; Prostatic Neoplasms; Prostatic Secretory Proteins; Salivary Proteins and Peptides; Seminal Plasma Proteins | 2010 |
Serum prostate-specific antigen levels reflect the androgen milieu in patients with localized prostate cancer receiving androgen deprivation therapy: Tumor malignant potential and androgen milieu.
Topics: Aged; Androgens; Antineoplastic Agents, Hormonal; Chi-Square Distribution; Flutamide; Goserelin; Humans; Male; Middle Aged; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome | 2010 |
Adrenocorticotropic hormone is involved in regulation of androgen synthesis in men receiving androgen deprivation therapy for localized prostate cancer.
Topics: Adrenocorticotropic Hormone; Aged; Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Flutamide; Goserelin; Humans; Male; Middle Aged; Prospective Studies; Prostatic Neoplasms | 2010 |
Insulin-like growth factor-1 is associated with regulation of the luteinizing hormone production in men receiving androgen deprivation therapy with gonadotropin-releasing hormone analogues for localized prostate cancer.
Topics: Adrenocorticotropic Hormone; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Dehydroepiandrosterone Sulfate; Flutamide; Goserelin; Human Growth Hormone; Humans; Immunoassay; Insulin-Like Growth Factor I; Logistic Models; Luteinizing Hormone; Male; Middle Aged; Multivariate Analysis; Outcome Assessment, Health Care; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Testosterone | 2012 |
Clinical efficacy of primary combined androgen blockade for Japanese men with clinically localized prostate cancer unsuitable for local definitive treatment: a single institution experience.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chlormadinone Acetate; Disease-Free Survival; Flutamide; Follow-Up Studies; Goserelin; Humans; Japan; Kaplan-Meier Estimate; Leuprolide; Male; Middle Aged; Neoplasm Staging; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Tosyl Compounds; Treatment Outcome | 2011 |
Mathematical modeling of prostate cancer progression in response to androgen ablation therapy.
Topics: Algorithms; Androgen Antagonists; Animals; Antineoplastic Agents, Hormonal; Cells, Cultured; Disease Progression; Drug Administration Schedule; Flutamide; Goserelin; Humans; Male; Models, Biological; Orchiectomy; Organ Size; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Rats; Rats, Sprague-Dawley; Receptors, Androgen; Testosterone; Treatment Outcome | 2011 |
Upfront androgen deprivation therapy with salvage radiation may improve biochemical outcomes in prostate cancer patients with post-prostatectomy rising PSA.
Topics: Analysis of Variance; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-Free Survival; Flutamide; Goserelin; Humans; Leuprolide; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Nitriles; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Radiotherapy Dosage; Retrospective Studies; Salvage Therapy; Seminal Vesicles; Tosyl Compounds | 2012 |
Choice of first-line treatment for metastatic prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Neoplasms; Estrogens; Flutamide; Goserelin; Humans; Male; Neoplasms, Hormone-Dependent; Orchiectomy; Prostatic Neoplasms; Time Factors; Treatment Outcome | 2013 |
Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Arrhythmias, Cardiac; California; Cardiovascular Diseases; Cohort Studies; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Heart Failure; Humans; Imidazolidines; Leuprolide; Male; Middle Aged; Multivariate Analysis; Neoplasm Grading; Nitriles; Proportional Hazards Models; Prospective Studies; Prostatic Neoplasms; Risk Factors; Tosyl Compounds | 2017 |
Status of the Microcirculatory Network as a Factor of Prognosis and Evaluation of Therapeutic Efficiency in Prostate Cancer Treated by High-Intensity Focused Ultrasound in Combination with Androgen Deprivation.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antigens, CD34; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Fibrosis; Flutamide; Follow-Up Studies; Goserelin; High-Intensity Focused Ultrasound Ablation; Humans; Male; Microcirculation; Middle Aged; Prognosis; Prostate; Prostatic Neoplasms; Treatment Outcome; Tumor Microenvironment | 2018 |
Androgen deprivation therapy and depression in men with prostate cancer treated with definitive radiation therapy.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Depression; Depressive Disorder; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Hospitalization; Humans; Imidazolidines; Leuprolide; Male; Mental Health Services; Middle Aged; Nitriles; Oligopeptides; Prostatic Neoplasms; Radiotherapy; Retrospective Studies; Suicide; Tosyl Compounds | 2019 |
Analysis of adverse event of interstitial lung disease in men with prostate cancer receiving hormone therapy using the Food and Drug Administration Adverse Event Reporting System.
Topics: Adverse Drug Reaction Reporting Systems; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Goserelin; Humans; Lung Diseases, Interstitial; Male; Prostatic Neoplasms; United States; United States Food and Drug Administration | 2023 |